September 15, 2008
Fusion From Carefx Goes Live at Cancer Therapy & Research Center, an NCI-Designated Cancer Center in Texas
SCOTTSDALE, Ariz., Sept. 15 /PRNewswire/ -- Carefx Corporation today announced that the nationally recognized Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio, Texas, has gone live after a 90-day implementation with Fusion from Carefx(R), an interoperability platform that aligns patient data across multiple applications to provide a complete view of patient health history.
One of only three National Cancer Institute-designated comprehensive cancer centers in Texas, CTRC, which was recently recognized as a Center of Excellence by the Myelodysplastic Syndromes Foundation, selected Fusion from Carefx for its ability to synchronize data from diverse systems including lab, pharmacy, medical records and PACs into a multidisciplinary view of patient records. As a result, CTRC clinicians can deliver care more efficiently.
"Fusion allows our care providers to access comprehensive summaries of patient data that parallel cancer care processes in a fraction of the time it took previously," said David Hotchkiss, CTRC's Director of Information Systems. "With Fusion, our multidisciplinary clinical care team is able to save precious time with the streamlined workflow and make more informed patient care decisions."
In use at nearly 300 facilities nationwide, Fusion from Carefx seamlessly integrates patient information from diverse applications and databases at the user-interface level. By implementing Fusion, CTRC has saved on expenses associated with deploying multiple interfaces for database integration and has kept its overall cost of ownership down. Fusion presents the user with a streamlined look at relevant clinical data, where and when the user needs it. Fusion reduces the time CTRC clinicians must invest in searching for and accessing information needed to diagnose and treat patients.
"Carefx worked closely with our team to understand the unique needs of CTRC and the approach we use in delivering care to cancer patients," Hotchkiss said. "Carefx took the time to clearly comprehend our requirements by analyzing workflows and understanding the optimal user experience. They delivered a solution that not only met our requirements but also beat an on-budget and aggressive 90-day implementation schedule."
"Carefx understands that CTRC, and every other healthcare organization, needs to leverage their existing technology investments," said Andrew Hurd, Chairman and CEO of Carefx. "We take great pride in solving the challenge of accessing patient data from multiple systems and removing time-wasting workflow obstacles, rapidly and cost effectively. As a company, we are driven by the desire to play our part in helping our customers improve clinical efficacy and quality care."
About Carefx Corporation
Scottsdale, Ariz.-based Carefx is the only provider of an open, scalable patient data aggregation platform that provides clinicians with real-time access to information residing in disparate clinical applications. Fusion from Carefx(R) can be operated either in a desktop or a web-based environment and is customizable to each user's workflow. For more information, visit http://www.carefx.com/ .
The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is one of the nation's leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only three in Texas. CTRC handles more than 120,000 patient visits each year and is a world leader in developing new drugs to treat cancer. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world, and participated in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit our Web site at http://www.ctrc.uthscsa.edu/ .
Carefx Media Contact: Christopher Capot KNB Communications 212-505-2441 [email protected]
CONTACT: Christopher Capot, KNB Communications, +1-212-505-2441,[email protected], for Carefx Corporation
Web site: http://www.carefx.com/http://www.ctrc.uthscsa.edu/